HSBC initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target The firm says the company’s ability to sustain its growth beyond the medium term is the key investor debate. However, Eylea HD uptake is accelerating in the short term and Regeneron’s oncology catalysts in 2026 support a potential re-rating of the shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Buy Rating: Growth Potential Driven by Eylea HD Uptake and Oncology Catalysts
- Early notable gainers among liquid option names on November 20th
- Video: Nvidia results ease AI bubble concerns, boost market
- Regeneron’s Promising Outlook: Overcoming Regulatory Hurdles and Expanding Eylea HD’s Market Potential
- Positive Outlook for Regeneron: Buy Rating Supported by Eylea HD Approval and Strong Portfolio